See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/236603790
Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 Website Article in The Journal of Rheumatology · May 2013 DOI: 10.3899/jrheum.130030 · Source: PubMed
CITATIONS
READS
16
60
3 authors: Zahi Touma
Murray Barry Urowitz
University of Toronto
University of Toronto
94 PUBLICATIONS 652 CITATIONS
340 PUBLICATIONS 13,936 CITATIONS
SEE PROFILE
SEE PROFILE
Dafna D Gladman University of Toronto 1,108 PUBLICATIONS 41,830 CITATIONS SEE PROFILE
All content following this page was uploaded by Zahi Touma on 24 April 2015. The user has requested enhancement of the downloaded file. All in-text references underlined in blue are added to the original document and are linked to publications on ResearchGate, letting you access and read them immediately.
The Journal of Rheumatology
Volume 40, no. 5
Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 Website ZAHI TOUMA, MURRAY B. UROWITZ and DAFNA D. GLADMAN J Rheumatol 2013;40;733 http://www.jrheum.org/content/40/5/733 1. Sign up for our monthly e-table of contents http://www.jrheum.org/cgi/alerts/etoc 2. Information on Subscriptions http://jrheum.com/subscribe.html 3. Have us contact your library about access options
[email protected] 4. Information on permissions/orders of reprints http://jrheum.com/reprints.html The Journal of Rheumatology is a monthly international serial edited by Earl D. Silverman featuring research articles on clinical subjects from scientists working in rheumatology and related fields.
Downloaded from www.jrheum.org on April 23, 2015 - Published by The Journal of Rheumatology
Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 Website To the Editor:
We read with great interest the editorial1 by David A. Isenberg related to our article, “Development and Assessment of Users’ Satisfaction with the Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 Website”2 (S2K RI-50). Dr. Isenberg states that a drawback of the S2K RI-50 is that it does not identify patients whose clinical features are worse. However, outcome measures in clinical trials in systemic lupus erythematosus (SLE) measure improvement from baseline, or flares over the course of the study from baseline. Both of these are well identified by Systemic Lupus Erythematosus Disease Activity Index (SLEDAI-2K) and S2K RI-50. Flares can certainly be ascertained by SLEDAI criteria (increase by 4 or more)3 and the S2K RI-50 identified an improvement that is less than complete resolution4. Thus the index has the necessary features to be a primary outcome measure in SLE drug trials. Unlike BILAG, it is simple, intuitive, and gives actual metrics for improvement, not lettered categories such as A, B, C, etc. The S2K RI-50 Website, www.s2k-ri-50.com, is currently being used to prepare clinicians to use the S2K RI-50 in clinical trials and research settings2. ZAHI TOUMA, MD, FACP, PhD, University of Toronto Lupus Clinic, Toronto Western Hospital, Centre for Prognosis Studies in the Rheumatic Diseases; MURRAY B. UROWITZ, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Toronto Western Research
Institute, Director, University of Toronto Lupus Clinic, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital; DAFNA D. GLADMAN, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Toronto Western Research Institute, Co-Director, University of Toronto Lupus Clinic, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada. Address correspondence to Dr. M.B. Urowitz, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Room 1E-409, 399 Bathurst Street, Toronto, Ontario M5T 2S8, Canada. E-mail:
[email protected]
REFERENCES 1. Isenberg DA. Rhubarb and reliability — A Jane Austen view of systemic lupus erythematosus [editorial]. J Rheumatol 2013;40:7-8. 2. Touma Z, Gladman DD, MacKinnon A, Carette S, Abu-Shakra M, Askanase A, et al. Development and assessment of users’ satisfaction with the Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 Website. J Rheumatol 2013;40:34-9. 3. Gladman DD, Urowitz MB, Kagal A, Hallett D. Accurately describing changes in disease activity in systemic lupus erythematosus. J Rheumatol 2000;27:377-9. 4. Touma Z, Gladman DD, Ibanez D, Urowitz MB. Development and initial validation of the Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index 50. J Rheumatol 2011;38:275-84.
J Rheumatol 2013;40:5; doi:10.3899/jrheum.130030
Personal non-commercial use only. The Journal of Rheumatology Copyright © 2013. All rights reserved.
Letter
Downloaded from www.jrheum.org on April 23, 2015 - Published by The Journal of Rheumatology View publication stats
733
